NewGenIvf Group Ltd

NewGenIvf Group Ltd has filed an F-1 registration statement for a proposed offering of up to 5,454,545 Class A Ordinary Shares at $1.10 per share, alongside pre-funded warrants. Additionally, selling securityholders intend to offer up to 4,364,044 Class A Ordinary Shares. The company, an assisted reproductive services provider in Asia-Pacific, reported revenue of US$4.73 million and a net income of US$9.73 million for the year ended December 31, 2025, a significant turnaround from a net loss of US$0.47 million on US$5.43 million revenue in 2024. The filing also details the company's history, including multiple reverse stock splits and its business operations in Thailand, Cambodia, and Kyrgyzstan.

NewGenIvf Group Limited announced that its total outstanding Class A shares now stand at 5,919,948. This increase is due to share issuances related to strategic agreements to acquire a 3% equity interest in K25.ai. Based on the closing trading price of $0.85 on July 30, 2026, the company's Market Value of Listed Securities reached US$5,031,956.

NewGenIvf Group Ltd provided an update on its strategic investment in K25.ai, announcing that its 13% stake is now valued at approximately US$26 million. This valuation, based on K25.ai's US$200 million implied valuation from its Series A round, represents an expected unrealized gain of about US$8.5 million, significantly strengthening NewGenIvf's balance sheet. The company also expects its total outstanding Class A ordinary shares to reach approximately 5.9 million following a recently announced issuance.

NewGenIvf Group Ltd announced it will acquire an additional 3% equity interest in K25.ai for US$7.5 million, increasing its total ownership to 13%. The investment values K25.ai at US$250 million, reflecting its successful community beta and market traction. NewGen will issue approximately 2.5 million Class A ordinary shares as consideration, which is expected to strengthen its market capitalization above the US$5 million Nasdaq threshold.

NewGenIvf Group Limited announced it has entered into a definitive agreement to acquire an additional 3% equity interest in PredicXion Group Limited (K25.ai) for US$7.5 million. This acquisition will increase NewGenIvf's aggregate ownership in K25.ai from 10% to 13%. The consideration includes US$3.75 million in cash or digital assets and 2.5 million newly issued Class A ordinary shares of NewGenIvf, valued at US$1.50 per share. The transaction values K25.ai at US$250 million and is expected to strengthen NewGenIvf's market capitalization above the US$5 million threshold, supporting Nasdaq listing compliance.

NewGenIvf Group Ltd announced an independent Big Four valuation of approximately $19 million for its planned UAE-based cell sorting and cytometry leasing business. This valuation highlights the significant growth potential in the high-infertility GCC market, projected to reach $444 million by 2030. The company also appointed industry veteran Nadeem Malik as Senior Strategic Advisor to spearhead the UAE/GCC expansion, leveraging his expertise in IVF and cell sorting operations.

NewGenIvf Group Limited announced that its Board of Directors approved a 1-for-3 reverse stock split for all issued and unissued shares, including Class A and Class B ordinary shares and preferred shares. The reverse stock split will be effective at 12:01 a.m. (ET) on July 6, 2026, with trading on a split-adjusted basis commencing the same day on the Nasdaq Capital Market under a new CUSIP number. This action will reduce the number of outstanding Class A Ordinary Shares from approximately 10.26 million to 3.42 million, with fractional shares being rounded up to a full share.

NewGenIvf Group Ltd announced the issuance of 3,666,667 new shares, bringing its total outstanding shares to 10,073,535. This action, linked to its strategic acquisition of a 10% equity interest in K25.ai, helped the company reach a market capitalization of US$7,631,710 as of June 18, 2026. The company also made a subsequent US$10 million investment in K25.ai, reinforcing its strategic pivot towards AI and digital platforms and positioning it to meet Nasdaq's minimum market value requirements.

NewGenIvf Group Limited announced an additional strategic investment in PredicXion Group Limited (K25.ai), acquiring an extra 4% equity for US$4 million. This increases NewGenIvf's total ownership in K25.ai to 10%, based on an implied valuation of US$100 million. The investment completes K25.ai's US$10 million Pre-A round, and the company is now raising its Series A to support product launch and regional expansion. NewGenIvf also holds exclusive Asia-Pacific agency rights with K25.ai, deepening its strategic participation.

NewGenIVF Group Limited announced a further $4 million strategic investment in K25.ai, completing K25.ai's $10 million Pre-A round at a $100 million valuation. This investment is expected to increase NewGen's aggregate ownership in K25.ai to 10%. With the Pre-A round closed, K25.ai has commenced its Series A fundraising to accelerate product launch and regional expansion, supported by NewGen's expanded stake and exclusive Asia-Pacific agency rights.